Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Crescendo Biologics (Formerly Translocus)

Request full access

Novel T-cell enhancing Humabody® therapeutics for immuno-oncology

Cambridge, United KingdomFounded 2009Biotech & Life Sciences

About Crescendo Biologics (Formerly Translocus)

Crescendo Biologics is a private, clinical-stage immuno-oncology company located in Cambridge, UK, that develops targeted T-cell enhancing therapeutics. Founded in 2007 and spun out of the Babraham Institute in 2009, the company leverages its proprietary, patent-protected transgenic mouse platform to generate fully human VH domain building blocks, known as Humabody® VH. This platform produces small, robust, and stable antibody fragments that can be configured into multi-functional therapeutics, offering superior tissue penetration and bio-distribution compared to conventional antibodies.

The company's business model revolves around advancing its proprietary pipeline and forming strategic collaborations with major pharmaceutical companies. Its revenue is generated through upfront payments, equity investments, research funding, and milestone payments from these partnerships, as well as future royalties on commercialized products. Crescendo has established significant multi-target discovery and development collaborations. A 2016 deal with Takeda focuses on developing Humabody®-based therapeutics for cancer, a partnership that was later expanded. In 2022, a collaboration was initiated with BioNTech to develop multi-specific precision immunotherapies, including mRNA-based antibodies and engineered cell therapies. Additionally, a 2018 worldwide licensing agreement with Zai Lab is centered on developing and commercializing ZL-1102 (formerly CB001), a topical Humabody® for inflammatory conditions like psoriasis, which has entered a global Phase 2 trial as of June 2024.

Crescendo's proprietary pipeline is led by CB307, a half-life extended CD137 x PSMA bispecific Humabody®. This candidate is designed to selectively activate tumor-specific T-cells within the tumor microenvironment, aiming for a durable anti-cancer effect while minimizing systemic toxicity. The clinical program for CB307 is underway in patients with PSMA-positive solid tumors (NCT04839991), with the first US patients dosed in late 2023. Other pipeline candidates include CB693, a CD137 x MSLN Humabody®, and CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody.

Source: Dealroom company data

At a glance

Status
Operational
Employees
10
Open positions
None listed
Dealroom signal
71.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Intellectual Property, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, uk is8 life sciences, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Jul 2023 $32M $314M Kreos Capital · IP Group · Andera Partners · Quan Capital ↗
LATE VCOther financing Jan 2022 $30M $314M BioNTech ↗
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

Crescendo Biologics (Formerly Translocus) website traffic

Latest recorded traffic for Crescendo Biologics (Formerly Translocus) is 800 monthly website visits, down 27.3% over the last three months. Crescendo Biologics (Formerly Translocus)'s team declined 9.1% over the past year.

Latest monthly visits800 3-month web change-27.3% 1-year team growth-9.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Crescendo Biologics (Formerly Translocus) in the Cambridge ecosystem

Live from Dealroom

The Crescendo Biologics (Formerly Translocus) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

Series A6 investors entered at this stage

  • Future Planet Capital
  • Imperial Innovations
  • Astellas Venture
  • EMBL Ventures
  • Andera Partners
  • Takeda Ventures

Series B and later4 investors entered at this stage

  • BioNTech
  • Kreos Capital
  • IP Group
  • Quan Capital
Team profiled 17 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇬🇧 United Kingdom100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Crescendo Biologics (Formerly Translocus) on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Crescendo Biologics (Formerly Translocus)’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.